Molecular PharmaGroup, New Providence, NJ

Is Molecular PharmaGroup an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Molecular PharmaGroup in New Providence, NJ, first registered May 8, 2018 and most recently registered Dec 30, 2025. FDA lists its last inspection as Aug 11, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Untitled Letter Issued 2/5/2026”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
New Providence, NJ
Initial registration
May 8, 2018
Most recent registration
Dec 30, 2025
Last inspection
Aug 11, 2025
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Untitled Letter Issued 2/5/2026
Intends to compound sterile drugs from bulk substances
Yes

FDA inspections and actions on record

No entry for this facility was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). FDA may list it under a different name, and the page covers actions from 2019 on.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Molecular PharmaGroup LLC, New Providence, NJ (FEI number 3014413265), matched to this page by exact name, city and state. It lists 2 inspections: 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Aug 11, 2025Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30144132651278107
Dec 11, 2023Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30144132651224590

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 28, 2025 to Aug 11, 2025: 3 observations

Firm on the cover
Molecular PharmaGroup LLC, 755 Central Ave Unit 2 Unit 4, New Providence, NJ 07974 -1116
FEI number
3014413265
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
Matched to this page by
FEI number on the cover; linked from 503B list, actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

Specifically,

The firm's ISO 5 <Redacted B4> Vertical Laminar Air Flow_(V-LAF) hood (Equipment ID: MPG~065), located m ISO 7 Room <Redacted B4> which is used for stenle filling of Ethanol 70% (v/v) into 5 mL syringes lacks a magnehelic gauge to measure the differential pressure between the ISO 5 LAF hood and ISO 7 room. There is no assurance that potential contaminants from the ISO 7 room do not enter the ISO 5 V -LAF during routine sterile filling operations. Batches of Ethanol 70% (v/v), including, but not limited to, batches# MFG-PC004(B)-021-25 (BUD: 24SEP2025), MFG-PC004(B)-023-25 (BUD: 13DEC2025), and MFG-PC004(B)-025-25 (BUD: 22DEC2025), have been filled in the ISO 5 V-LAF and released for distribution.

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

1) The firm's airflow visualization (smoke) studies do not simulate the following interventions, including, but not limited to, those listed below that have been included during the firm's Aseptic Process Simulations and which could occur during the sterile filling of Ethanol 70% (v/v) into 5 mL syringes within the ISO 5 V-LAF hood (Equipment ID: MPG-065):

• While filling is underway, an operator steps out from the V-LAF, then introduces new materials into the hood, and steps back into the V-LAF.

• Pause filling operations while an operator steps out from the V-LAF, introduces a new Sterile <Redacted B4> Transfer Accessory for Pharmacy Transfer Tubing (PTT) Set and a Sterile Pharmacy Transfer Tubing with <Redacted B4> Inlet <Redacted B4> Pump Insert into the hood, replaces them and resume filling operations. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Written procedures are not established for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.

Specifically,

The firm has not established a written procedure for conducting Annual Product Reviews (APRs). Additionally, the firm failed to conduct Annual Product Reviews for approximately <Redacted B4> batches of Ethanol 70% Injection(v/v) manufactured in 2024 to evaluate quality standards and determine the need for changes in drug product specifications or procedures.

of Ethanol 70% Injection(v/v) manufactured in 2024 to evaluate quality standards and detennine the need for changes in drng product specifications or procedures.

GLP-1 records in this index

No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Molecular PharmaGroup). That is not a finding beyond this index’s search.

The Molecular PharmaGroup pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.